The effective development of a therapeutic requires the ability to quickly and robustly validate that it is having expected actions on its target. In this webinar, Dr. Wayne Doyle, a senior Bioinformatics Scientist at Eclipsebio, will review two assays and analyses that can assist in the development of RNA therapeutics. eRibo Pro is a ribosome profiling assay for examining both transcription and translation in the same system. Dr. Doyle will discuss Eclipsebio’s analyses for identifying changes in translation, pinpointing stalled ribosomes, and discovering translating open reading frames. miR-eCLIP +siRNA is an eCLIP-based method for directly identifying where miRNAs and siRNAs associate with genes across the transcriptome. Dr. Doyle will review how Eclipsebio determines miRNA binding, calls siRNA off targets, and identifies differential effects from siRNA modifications.
Brought to you by the Boston Computational Biology Society, Eclipsebio, PTP Infinite Innovations, 10X Genomics, and biomodal.
About the speaker
Wayne obtained his PhD in Neuroscience from UT Southwestern, and then did a postdoc at UCSD where we contributed to the single cell sequencing analyses performed as part of the BRAIN Initiative Cell Census Network’s (BICCN) mapping of the mouse brain. He then worked at the epigenetics company Active Motif, as a bioinformatics scientist and manager, focusing on customer sample processing and the development of new kits and services. He is currently a Senior Bioinformatics Scientist and User Experience Lead at Eclipsebio. Eclipsebio is a private biotechnology company headquartered in San Diego, developing first-in-class technologies to accelerate the development of tomorrow’s key RNA genomics discoveries and medicines